TLX is trading 4.7% up today at $11.16 as buyers step in following recent weakness and positive clinical developments.
- Telix is highlighting its neuro-oncology pipeline via an educational webinar scheduled for June 29.
- Sentiment is being bolstered by visibility around the ProstACT Global Phase 3 prostate cancer program, which was featured as a late-breaking presentation at ASCO 2026.